

Curriculum vitae

Personal information

Surname/Given names **Moccia, Alden Alberto**
Address Oncology Institute of Southern Switzerland (IOSI)
Ospedale Regionale di Locarno "La Carità"
Via Ospedale 1
CH-6600 Locarno
Telephone +41-91-811-4764 (office)
E-mail alden.moccia@eoc.ch
Nationality swiss
Date of birth June 26th, 1975

Work experience

02/2011 - to date Department of Medical Oncology
Oncology Institute of Southern Switzerland (IOSI)
Ospedale Regionale di Lugano (Italiano), Lugano, Switzerland
Prof. M. Ghielmini

02/2009 – 01/2011 Department of Medical Oncology
British Columbia Cancer Agency, Vancouver, BC, V5Z 4E6, Canada
Prof. J. M. Connors and Prof. L. H. Sehn

04/2006 – 12/2008 Department of Medical Oncology
Oncology Institute of Southern Switzerland (IOSI)
Ospedale Regionale Bellinzona e Valli, Switzerland
Prof. M. Ghielmini and Prof. F. Cavalli

04/2004 – 03/2006 Dept. of Internal Medicine
CHUV, University of Lausanne, Switzerland
Prof. P. Nicod and Prof. G. Waeber
(6 months in Medical Oncology Dept. (Prof. S. Leyvraz) and 6 months in
Hematology Dept. (Prof. M. Shapira))

01/2002 – 02.2004 Dept. of Internal Medicine
Hospital of District Locarno, Switzerland
PD G. Mombelli

02/2001 – 12.2001 Dept. of Internal Medicine
Clinica Fondazione Varini, Orselina, Switzerland
Dr. B. Galli

Education and training

2012	Title of specialist in Medical Oncology (FMH)
2009-2011	Fellowship, British Columbia Cancer Agency, Vancouver, Canada (J. M. Connors, MD and L. H. Sehn, MD, MPH)
2008	State Board Examinations, FMH and ESMO, Medical Oncology
2004 – 2008	Trainee (Clinical Oncology)
2008	Title of specialist in Internal Medicine (FMH)
2008	Doctoral Thesis: The role of Non invasive Ventilation in Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). University of Lausanne, Switzerland.
25/10/2004	State Board Examination, FMH Internal Medicine
2001 – 2004	Trainee (Internal Medicine)
2000	State board Examination, Medicine, University of Lausanne, Switzerland
1994 – 2000	Medical studies, University of Lausanne, Switzerland
1990 – 1994	High-school with emphasis on sciences, Locarno, Switzerland

Publications

Steffanoni S, Ghielmini M, [Moccia AA](#). Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. *Expert Rev Anticancer Ther*. 2015 Sep 28:1-13.

Conconi A, Franceschetti S, Aprile von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, [Moccia AA](#), Bertoni F, Ramponi A, Mazzucchelli L, Cavalli F, Gaidano G, Zucca E. Histologic Transformation in Marginal Zone Lymphomas. *Ann Oncol*. 2015 Sep 23.

Conconi A, Lobetti-Bodoni C, Montoto S, Lopez-Guillermo A, Coutinho R, Matthews J, Franceschetti S, Bertoni F, [Moccia AA](#), Rancoita PM, Gribben J, Cavalli F, Gaidano G, Lister A, Montserrat E, Ghielmini M, Zucca E. Life expectancy of young adults with follicular lymphoma. *Ann Oncol*. 2015 Sep 11.

Hitz F, Connors JM, Gascoyne RD, Hoskins P, [Moccia AA](#), Savage KJ, Sehn LH, Shenkier T, Villa D, Klasa R. Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment. *Ann Hematol*. 2015 Aug 7.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, [Moccia AA](#), Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberger D, Möller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. *Lancet Oncol*. 2015 Aug 6.

Kridel R, Xerri L, Gelas-Dore B, Tan K, Feugier P, Vawda A, Canioni D, Farinha P, Boussetta S, [Moccia AA](#), Brice P, Chavez EA, Kyle AH, Scott DW, Sanders AD, Fabiani B, Slack GW, Minchinton AI, Haioun C, Connors JM, Sehn LH, Steidl C, Gascoyne RD, Salles G. The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association. *Clin Cancer Res*. 2015 Aug 1;21(15):3428-35.

Aprile von Hohenstaufen K, [Moccia AA](#), Zucca E. Mantle cell lymphoma. *Future Science* 2013

Gobba S, [Moccia AA](#), Stussi G, Mazzucchelli L, Zucca E, Espeli V. Extranodal NK/T-cell lymphoma with leukaemic presentation. *Br J Haematol* 2013 Jun;161(6):754.

Li ZM, Ghielmini M, [Moccia AA](#). Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. *Expert Rev Anticancer Ther* 2013 Mar;13(3):313-325.

[Moccia AA](#), Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. International Prognostic Score in advanced-stage Hodgkin's lymphoma: altered utility in the modern era. *J Clin Oncol* 2012 Sep 20;30(27):3383-3388.

Conconi A, Ponzio C, Lobetti-Bodoni C, Motta M, Rancoita PM, Stathis A, [Moccia AA](#), Mazzucchelli L, Bertoni F, Ghielmini M, Cavalli F, Zucca E. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. *Br J Haematol* 2012 Apr;157(2):188-196.

[Moccia AA](#), Mingrone W. Follikuläre Lymphome. *Schweizer Zeitschrift für Oncologie* 2008 4: 24-27.

Domenighetti G, [Moccia AA](#), Gayer R. Observational case-control study of non-invasive ventilation in patients with ARDS. *Monaldi Arch Chest Dis* 2008 Mar;69(1):5-10.

[Moccia AA](#), Ghielmini M. Monoclonal antibodies for the treatment of hematologic malignancies: schedule and maintenance therapy. *Semin Hematol* 2008 Apr;45(2):75-84.

[Moccia AA](#), Ghielmini M. Therapieleitfaden maligne Lymphome. Kapitel 2. Uni-med verlag Bremen London Boston. Editor Mario Barghetzi. 1. und 2. Aufgabe (2009 and 2011)

Belisario VF, Froesch P, Wannesson L, Moccia AA, Pedrazzini A, Mazzucchelli L, Cavalli F, Zucca E. A very uncommon disease. SAKK Bulletin 2007

Moccia AA, Ghielmini M, Mingrone W, Bargetzi M. Therapieleitfaden maligne Lymphome (in German). Chapter I. UNI-MED Bremen 2008.

Publications submitted for publication

Moccia AA, Hitz F, Hoskins P, Klasa R, Power MM, Savage KJ, Shenkier T, Shepherd JD, GW Slack, Song KW, Gascoyne RD, Joseph M. Connors JM and Sehn LH. Gemcitabine, Dexamethasone, and Cisplatin (GDP) is an Effective and Well-Tolerated Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma. SUBMITTED

Moccia AA, Hoskins P, Klasa R, Savage KJ, Shenkier T, Shepherd JD, Gascoyne RD, Joseph M. Connors JM and Sehn LH. R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcomes in Patients with Diffuse Large B-Cell Lymphoma and a Contraindication to Anthracyclines. SUBMITTED

Other scientific activities

Swiss Coordinating Investigator for SAKK of the HD21 trial of German Hodgkin Study Group (GHSG)

Reviewer for *Annals of Oncology*, *Swiss Medical Weekly*, *Hematological Oncology*, *European Journal of Internal Medicine*

Abstract reviewer for *International Congress of Malignant Lymphoma* (IMCL) in Lugano (2011 and 2013), *European Haematology Association* (EHA) Annual Meeting in Milan (2014)

Languages

Italian (mother tongue),
Fluent in English and French
Facility with German

Memberships

Swiss Medical Association (FMH)
Swiss Group for Clinical Cancer Research (SAKK), Lymphoma Project Group
International Extranodal Lymphoma Study Group (IELSG)

Other interests

Climbing (SAC/CAS Member), skiing, photography, architecture.

Alden Moccia, MD
01/2016